| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Cash flows used in operating activities: | | | | | | | | |
| Net loss | -77.1 | -169.6 | -148.3 | -35.3 | -25.6 | -1.4 | 8.3 | 9.3 |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Depreciation | 0.4 | 0.7 | 0.4 | 0.3 | 0.7 | 0.3 | 0.1 | 0.1 |
| Amortization of intangibles | | | | | | 2.9 | 2.2 | 1.2 |
| Amortization of deferred financing costs | 3.3 | 2.4 | 2.7 | 2.3 | 1.3 | | | |
| Accretion expense | 8.6 | 6.5 | 5.0 | 2.3 | 1.3 | | | |
| Stock compensation expense | 2.5 | 2.7 | 5.9 | 4.7 | 2.0 | 2.7 | 1.3 | 0.5 |
| Fair market value change in contingent consideration | -1.0 | -11.7 | -0.1 | | 7.6 | | | |
| Fair market value change in derivative liability | 0.0 | -8.9 | -19.3 | | | | | |
| Gain from legal settlement | -10.5 | | | | | | | |
| Gain from exchange of debt | -14.7 | | 1.1 | | | | | |
| Impairment of fixed assets | 18.5 | 56.1 | | | | | 0.4 | |
| Gain on sale of assets | | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | | |
| (Increase) decrease in operating assets, net of effects of acquisitions: | | | | | | | | |
| Accounts receivable | 5.4 | 11.0 | -17.1 | -18.5 | 12.2 | -3.9 | -5.8 | -8.4 |
| Income tax receivable | 1.3 | 5.3 | -4.1 | -6.6 | 0.6 | | | 2.0 |
| Inventory | 2.4 | 2.3 | 0.4 | 1.9 | 7.4 | -0.7 | -2.1 | -1.3 |
| Prepaid expenses and other assets | 3.8 | -0.5 | 2.5 | -2.1 | -2.2 | -0.2 | -0.3 | 0.2 |
| Increase (decrease) in operating liabilities, net of effects of acquisitions: | | | | | | | | |
| Accounts payable and accrued expenses | -2.1 | -8.0 | 6.7 | 12.2 | -3.4 | -1.8 | 0.7 | 1.6 |
| Accrued allowances | -4.7 | -1.7 | 10.1 | 18.3 | -3.1 | | | |
| Interest payable | -0.5 | -1.0 | 2.3 | 10.0 | 0.1 | | | |
| Other liabilities | -2.2 | -2.6 | -5.0 | -4.7 | 10.2 | | | |
| Net cash used in operating activities | -5.9 | -16.5 | -14.7 | 8.9 | -6.5 | -1.9 | 9.4 | 4.7 |
| Cash flows from investing activities: | | | | | | | | |
| Acquisition of Orexigen, net of cash acquired | | -0.6 | -88.0 | -255.0 | -0.3 | -62.0 | | -1.5 |
| Proceeds from sale of non-core assets | 2.0 | | | 0.0 | 0.0 | 0.0 | | |
| Purchase of software and equipment | 0.0 | -1.0 | -1.2 | -1.2 | -0.5 | -0.3 | -0.2 | -0.1 |
| Net cash used in investing activities | 2.0 | -1.6 | -84.3 | -249.9 | 23.4 | -64.9 | -2.2 | -5.7 |
| |
| Cash flows from financing activities: | | | | | | | | |
| Proceeds from issuance of convertible notes | | | | | | | | |
| Tax benefit on stock-based awards | | | | | | | | |
| Proceeds from exercise of stock options | | | | | | | | |
| Payments on Treximet Secured Notes | -17.5 | -20.4 | | | | | | |
| Payment on financing costs | -13.6 | | -5.3 | -14.1 | | | | |
| Net payments on credit facilities | 0.2 | -1.0 | 137.7 | 55.5 | -25.2 | 40.1 | | |
| Payments on mortgages and capital leases | -0.1 | -0.1 | 0.0 | 0.0 | -0.1 | | | |
| Proceeds from issuance of common stock, net of tax and costs | | | | | | 24.6 | 19.5 | 0.1 |
| Shares withheld for the payment of taxes | -0.1 | 0.0 | | | | | | |
| Stock issuance costs | | | | | | 0.8 | 0.3 | |
| Net cash provided by financing activities | 0.4 | -1.7 | 120.4 | 260.2 | -24.2 | 55.3 | 19.1 | 4.7 |
| Net decrease in cash and cash equivalents | -3.6 | -19.8 | 21.3 | 19.2 | -7.4 | -11.5 | 26.3 | 3.7 |
| Cash and cash equivalents, beginning of period | 36.4 | 56.1 | 34.9 | 15.6 | 23.0 | 34.6 | 8.3 | 4.6 |
| Cash and cash equivalents, end of period | 32.8 | 36.4 | 56.1 | 34.9 | 15.6 | 23.0 | 34.6 | 8.3 |